How Western Switzerland’s neurosciences cluster is turning research into innovation.
Within a decade, Western Switzerland has become the Health Valley, a world-class laboratory for discovering and developing the healthcare of the future. Thanks to many visionary individuals, exceptional infrastructures and financial support, the Bioalps life sciences cluster has become one of the most dynamic and innovative in Europe. This “Odyssée by Bilan” offers a deep dive into the spectacular expansion of neurosciences in the Bioalps Health Valley. From fundamental research to start-up they have become key ingredients to make this region one of the fastest growing life sciences clusters in the world.
Discover the latest news and trends about the secrets of the brain through this Bilan special webdoc edition. You can access the document following this link.
Swiss eHealth Summit 201811.09.2018L'événement se déroulera le 11 et 12 septembre 2018 au Stade de Suisse à Berne, sous le thème "Leadership &...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.